#United States #Phoenix #Wound Care #BioLab Holdings #Animal Study

BioLab Holdings' New Wound Care Product Study

BioLab Holdings, Inc., based in Phoenix, has conducted an extensive 25-day animal study to evaluate the effectiveness of their latest wound care innovation. This new product is a gelatinous skin treatment that conforms to wounds effectively and boasts a high protein concentration, which its developers believe could have far-reaching implications for the field of wound healing. Dr. Carlos Encinas, the chief science officer at BioLab, emphasized the importance of this breakthrough, stating that unlike traditional treatments, the new product does not require a donor biopsy, positioning it as a potential game-changer in the market.

The study took place over a period of 25 days and involved a sample of pigs, which are often used in preclinical testing due to their physiological similarities to humans. The primary objectives included assessing various healing metrics, blood analysis, animal welfare, and ensuring the product's safety throughout the treatment period. Impressively, the results indicated that wounds treated with BioLab’s gelatinous product healed faster compared to both the control group, which received a saline solution, and a competitor product.

For the study, 25 pigs were randomly organized into three groups. One group received the test item (BioLab's new product), another was treated with a reference item (the competitor product), and the last was assigned a saline solution as a control measure. The wounds on the pigs' backs were subjected to thorough evaluations spanning short-term, mid-term, and long-term healing assessments. Throughout the study, animal welfare was meticulously monitored, with wound measurements and photographic documentation conducted at each stage. Blood sampling was also performed to analyze various parameters, including biochemistry and hematology, which contributed to a comprehensive understanding of the product's effectiveness.

While results for short-term wound healing did not present significant differences among the groups, the long-term effects indicated accelerated healing for the test item in comparison to both the reference and control groups. Additionally, secondary outcomes, which included exudate levels, scab formation, and infection rates, did not show any significant variances. This suggests that the innovative product may have a favorable impact on overall wound healing outcomes. Notably, the administration of the gel on deep skin wounds proved to be well-tolerated by the subjects, further underscoring its promise as a reliable treatment option.

With the groundwork laid out and positive findings emerging from this research, BioLab is keen on sharing further developments regarding the anticipated launch of the product later this year. Those interested in learning more about BioLab Holdings, Inc., or exploring their range of wound care products, can visit their official website at biolabholdings.net.

About BioLab Holdings

BioLab Holdings, Inc. specializes in producing high-quality wound healing solutions, including their notable products like Membrane Wrap Lite™, Tri-Membrane Wrap™, and Hydro variant products. All of their offerings utilize human tissue allograft derived from amniotic membrane to provide effective wound protection. Emphasizing minimal manipulation to preserve natural tissue properties, BioLab remains dedicated to continuous innovation and delivering superior customer service. For more details, please refer to their website.